E. Nelson

发表

Microtubule-Targeted Chemotherapeutic Agents Inhibit Signal Transducer and Activator of Transcription 3 (STAT3) Signaling

D. Frank, S. R. Walker, Mousumi Chaudhury, 2010, Molecular Pharmacology.

Reciprocal Effects of STAT5 and STAT3 in Breast Cancer

A. Richardson, L. Zou, S. Signoretti, 2009, Molecular Cancer Research.

Reciprocal Effects of STAT 5 and STAT 3 in Breast Cancer

A. Richardson, L. Zou, S. Signoretti, 2009 .

STAT5 represses BCL6 expression by binding to a regulatory region frequently mutated in lymphomas

D. Frank, S. R. Walker, E. Nelson, 2007, Oncogene.

The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors.

B. Ebert, J. Griffin, D. Frank, 2011, Blood.

STAT signaling in the pathogenesis and treatment of myeloid malignancies

D. Frank, Michael Xiang, E. Nelson, 2012, JAK-STAT.

Dual inhibition of Jak2 and STAT5 enhances killing of myeloproliferative neoplasia cells

D. Frank, S. R. Walker, E. Nelson, 2012, Leukemia.

Induction of granulocytic differentiation by 2 pathways.

K. Akashi, D. Tenen, A. Friedman, 2002, Blood.

Reversible Resistance Induced by FLT3 Inhibition: A Novel Resistance Mechanism in Mutant FLT3-Expressing Cells

Chengsheng Zhang, J. Griffin, E. Fox, 2011, PloS one.

Targeting STAT 5 in Hematologic Malignancies through Inhibition of the Bromodomain and Extra-Terminal ( BET ) Bromodomain Protein BRD 2

J. Qi, J. Bradner, R. Stone, 2014 .

The STAT5 Inhibitor Pimozide Displays Efficacy in Models of Acute Myelogenous Leukemia Driven by FLT3 Mutations.

J. Griffin, A. Christie, A. Kung, 2012, Genes & cancer.

Smac mimetics: implications for enhancement of targeted therapies in leukemia

D. Porter, L. Zawel, A. Christie, 2010, Leukemia.

cells -mediated induction of granulopoietic development of hematopoietic α The amino terminal and E2F interaction domains are critical for C/EBP

D. Tenen, F. D'Alo', H. Radomska, 2013 .

The amino terminal and E2F interaction domains are critical for C/EBPα-mediated induction of granulopoietic development of hematopoietic cells Running Head: C/EBPα mediated granulopoietic development Scientific Section Heading: Hematopoiesis

D. Tenen, F. D'Alo', H. Radomska, 2003 .

An amino-indazole scaffold with spectrum selective kinase inhibition of FLT3, PDGFRα and kit.

P. Jänne, N. Gray, Wenjun Zhou, 2012, Bioorganic & medicinal chemistry letters.

Targeting STAT5 in Hematologic Malignancies through Inhibition of the Bromodomain and Extra-Terminal (BET) Bromodomain Protein BRD2

J. Qi, J. Bradner, R. Stone, 2014, Molecular Cancer Therapeutics.

The amino terminal and E2F interaction domains are critical for C/EBP alpha-mediated induction of granulopoietic development of hematopoietic cells.

D. Tenen, F. D'Alo', H. Radomska, 2003, Blood.

Modulators of STAT Transcription Factors for the Targeted Therapy of Cancer (STAT3 Inhibitors)

P. Hodder, Franck Madoux, M. Cameron, 2011 .

IL-2 regulates FOXP3 expression in human CD4+CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo.

J. Ritz, R. Soiffer, D. Frank, 2006, Blood.

Nifuroxazide inhibits survival of multiple myeloma cells by directly inhibiting STAT3.

D. Chauhan, T. Hideshima, D. Frank, 2008, Blood.

Pyrimethamine inhibits adult polycystic kidney disease by modulating STAT signaling pathways.

A. Takakura, Jing Zhou, D. Frank, 2011, Human molecular genetics.

Selective Akt Inhibitors Synergize with Tyrosine Kinase Inhibitors and Effectively Override Stroma-Associated Cytoprotection of Mutant FLT3-Positive AML Cells

N. Gray, Qingsong Liu, C. Mitsiades, 2013, PloS one.

Jak/STAT Signaling in the Pathogenesis and Treatment of Multiple Myeloma

D. Frank, E. Nelson, Sarah R Walker, 2013 .

Inhibition of Wild-Type p53-Expressing AML by the Novel Small Molecule HDM2 Inhibitor CGM097

M. Wiesmann, J. Griffin, Irene Simkin, 2015, Molecular Cancer Therapeutics.

Antimyeloma Activity of a Multitargeted Kinase Inhibitor, AT9283, via Potent Aurora Kinase and STAT3 Inhibition Either Alone or in Combination with Lenalidomide

N. Munshi, S. Rodig, Yiguo Hu, 2011, Clinical Cancer Research.

RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma

Y. Bang, R. Salgia, E. Vokes, 2011, Cancer biology & therapy.

A Chemical Biology Approach to Developing STAT Inhibitors: Molecular Strategies for Accelerating Clinical Translation

Sreenath V. Sharma, J. Settleman, D. Frank, 2011, Oncotarget.

CDK5RAP3 is a co-factor for the oncogenic transcription factor STAT3

D. Frank, Michael Xiang, E. Nelson, 2019, Neoplasia.

STAT5 Outcompetes STAT3 To Regulate the Expression of the Oncogenic Transcriptional Modulator BCL6

Guocheng Yuan, D. Frank, J. Yeh, 2013, Molecular and Cellular Biology.

Isolation of Unique STAT5 Targets by Chromatin Immunoprecipitation-based Gene Identification*

D. Frank, James V. Alvarez, E. Nelson, 2004, Journal of Biological Chemistry.

Discovery and Characterization of Novel Mutant FLT3 Kinase Inhibitors

N. Gray, Wenjun Zhou, H. Choi, 2010, Molecular Cancer Therapeutics.

Identification of Wee1 as a novel therapeutic target for mutant RAS-driven acute leukemia and other malignancies

N. Gray, C. Mitsiades, J. Griffin, 2014, Leukemia.

Antileukemic effects of the novel, mutant FLT3 inhibitor NVP-AST487: effects on PKC412-sensitive and -resistant FLT3-expressing cells.

Pascal Furet, Guido Bold, Arghya Ray, 2008, Blood.

Upregulation of IGF1R by Mutant RAS in Leukemia and Potentiation of RAS Signaling Inhibitors by Small-Molecule Inhibition of IGF1R

Kwok-Kin Wong, N. Gray, Qingsong Liu, 2014, Clinical Cancer Research.

Using combination therapy to override stromal-mediated chemoresistance in mutant FLT3-positive AML: synergism between FLT3 inhibitors, dasatinib/multi-targeted inhibitors and JAK inhibitors

N. Gray, Qingsong Liu, W. Hur, 2012, Leukemia.

Identification of Human STAT5-dependent Gene Regulatory Elements Based on Interspecies Homology*

X. Liu, D. Frank, E. Nelson, 2006, Journal of Biological Chemistry.

Combining the FLT3 Inhibitor PKC412 and the Triterpenoid CDDO-Me Synergistically Induces Apoptosis in Acute Myeloid Leukemia with the Internal Tandem Duplication Mutation

D. Kufe, I. Galinsky, R. Stone, 2010, Molecular Cancer Research.

Smac mimetics: implications for enhancement of targeted therapies in leukemia

D. Porter, L. Zawel, A. Christie, 2011, Leukemia.

Targeting constitutively active STAT3 in chronic lymphocytic leukemia: A clinical trial of the STAT3 inhibitor pyrimethamine with pharmacodynamic analyses

Zachary T. Giaccone, S. Tyekucheva, Catherine J. Wu, 2020, American journal of hematology.

AT9283, a Small Molecule Multi-Targeted Kinase Inhibitor with Potent Activity Against Aurora Kinase and STAT3 In Combination with Lenalidomide Results In Synergistic Anti-Myeloma Activity

N. Munshi, Yiguo Hu, D. Chauhan, 2010 .

Pimozide Inhibits STAT5 Signaling in Chronic Myelogenous Leukemia and Reduces the Viability of Both Imatinib Sensitive and Imatinib Resistant Cells.

D. Frank, E. Nelson, L. Gashin, 2007 .

Nifuroxazide Inhibits STAT3 Function and Shows Potent Anti-Tumor Activity Against Multiple Myeloma.

D. Chauhan, T. Hideshima, D. Frank, 2006 .

Targeting STAT5 in Hematologic Malignancies through Inhibition of the Bromodomain and Extra-Terminal (BET) Bromodomain Protein BRD2

J. Qi, J. Bradner, R. Stone, 2014, Molecular Cancer Therapeutics.

Microtubule-targeted chemotherapeutic agents inhibit STAT3 signaling in breast cancer

D. Frank, Mousumi Chaudhury, E. Nelson, 2008 .

Nifuroxazide inhibits survival of multiple myeloma cells by directly inhibiting STAT3.

D. Chauhan, T. Hideshima, D. Frank, 2008, Blood.